Dr. Harismendy graduated with an M.S. in Process Engineering from ENSTA-ParisTech (France) and a joint M.S. in Microbiology from the Pasteur Institute and Paris 7 University. He obtained his PhD in Microbiology from the same university, studying RNA polymerase III transcriptional regulation in yeast using ChIP-chip at Dr Sentenac’s laboratory (CEA-Saclay, France). He then joined Dr. Edelman’s Department of Neurobiology at The Scripps Research Institute (La Jolla, CA), where he developed ChIP-Seq approaches to study Neuron Restrictive Silencing Factor DNA binding in mouse developing brains. Under the mentorship of Dr Kelly Frazer, Dr. Harismendy went on to develop applications of high throughput sequencing for translational research : evaluating methods for targeted sequencing, exploring the role of regulatory variants in common diseases, and detecting and studying the role of somatic mutations in cancer. He joined the UC San Diego Moores Cancer Center in 2009 where he is currently leading the Oncogenomics laboratory. His current research focuses on the development of assays and computational approaches to study tumor heterogeneity predict drug response and understand the contribution of gene regulatory elements in cancer etiology and progression. Strong of his experience in the molecular analysis of clinical samples and the interpretation of the data for cancer care, Dr Harismendy participates in the molecular tumor board and the protocol monitoring and review committee to review and advise on the design and execution of molecularly guided clinical trials.Dr. Harismendy graduated with an M.S. in Process Engineering from ENSTA-ParisTech (France) and a joint M.S. in Microbiology from the Pasteur Institute and Paris 7 University. He obtained his PhD in Microbiology from the same university, studying RNA polymerase III transcriptional regulation in yeast using ChIP-chip at Dr Sentenac’s laboratory (CEA-Saclay, France). He then joined Dr. Edelman’s Department of Neurobiology at The Scripps Research Institute (La Jolla, CA), where he developed ChIP-Seq approaches to study Neuron Restrictive Silencing Factor DNA binding in mouse developing brains. Under the mentorship of Dr Kelly Frazer, Dr. Harismendy went on to develop applications of high throughput sequencing for translational research : evaluating methods for targeted sequencing, exploring the role of regulatory variants in common diseases, and detecting and studying the role of somatic mutations in cancer. He joined the UC San Diego Moores Cancer Center in 2009 where he is currently leading the Oncogenomics laboratory. His current research focuses on the development of assays and computational approaches to study tumor heterogeneity predict drug response and understand the contribution of gene regulatory elements in cancer etiology and progression. Strong of his experience in the molecular analysis of clinical samples and the interpretation of the data for cancer care, Dr Harismendy participates in the molecular tumor board and the protocol monitoring and review committee to review and advise on the design and execution of molecularly guided clinical trials.

electrochemical energy storage, control of thermal energy, and fluid flow at the nanoscale